FERQUITA STOKES: Open Payments
NPI 1629374491 · DELAND, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,033 in 75 payments from 14 companies in 2025. Trend: 2023 $1,277 · 2024 $2,078 · 2025 $2,033
Food & beverage: $2,033
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $500 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $304 |
| ABBVIE INC. | 10 | $285 |
| Neurocrine BioSciences, Inc. | 11 | $275 |
| E.R. Squibb & Sons, L.L.C. | 7 | $145 |
| Alkermes, Inc. | 4 | $119 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| Axsome Therapeutics, Inc. | 3 | $101 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Lundbeck LLC | 3 | $56 |
Products named: REXULTI, CAPLYTA, VRAYLAR, INGREZZA, COBENFY, ABILIFY MAINTENA, ARISTADA, Auvelity.
Industry payments across FL — which companies pay providers there.
